Authors
Latest:
Multidisciplinary Approaches to GVHDMedical experts discuss multidisciplinary approaches to GVHD.
Latest:
Dr Coopey on Institutional and Societal Initiatives to Support Women in OncologySuzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.
Latest:
Piecing Together the Proper BTK Usage in CLLNicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.
Latest:
The Future of Molecular Testing in NSCLCThe panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Latest:
Dr. Dumbrava on the Mechanism of Action of BDC-1001 in Advanced HER2-Expressing Breast CancerEcaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.
Latest:
Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R MyelomaAttaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.
Latest:
Hurwitz on the Safety Profile of Simultaneous Integrated Boost Plus SBRT in Prostate CancerJoshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.
Latest:
New Cancer Study Results Confirm Lasting Effects on 9/11 First RespondersResearch investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Latest:
SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer DisparitiesEdith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.
Latest:
Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver MetastasesMario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.
Latest:
Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed MyelomaPatients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.
Latest:
Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBCRoger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.
Latest:
Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical CancerJyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.
Latest:
Closing Expert Perspectives on Treatment in Advanced NSCLCLung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Latest:
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MDChandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.
Latest:
Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN TrialBoris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.
Latest:
Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup AnalysisExpert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
Latest:
Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual AnemiaRegis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
Latest:
Future Directions in Chronic GvHDDr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.
Latest:
Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL ManagementMikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.
Latest:
Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic MalignanciesSteven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.
Latest:
Improving outcomes in metastatic pancreatic cancerPancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.
Latest:
Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With CancerGeorge Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.
Latest:
Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid BiopsiesPaz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.
Latest:
Future Perspectives in the Treatment of NeuroblastomaGiselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.
